Welcome
Dr. Chad E. Beyer is a pharmaceutical executive with more than two decades of experience in the biopharmaceutical industry.
Dr. Beyer has experience in creating and leading R&D portfolios across several therapeutic areas in both big and small pharma environments, and he is passionate about leading, encouraging, and driving strategy with KOLs and industry thought leaders. Dr. Beyer has a successful track record of building, leading and working with high-performing cross-functional teams ranging from preclinical to clinical to regulatory to CMC to BD domains. He has worked across the industry from bench scientist to Head of Neurochemistry and has participated in the submission of 34 INDs and operationalized more than 10 Phase 1 / Phase 2 studies.
Most recently, Dr. Beyer served as CEO of Kures, a private, clinical-stage company focused on precision neuropsychiatry and addiction where, in addition to completing key pharmacodynamic clinical trials, he led the transaction of the company. Previously, Dr. Beyer served as CEO and SVP of R&D at Promentis Pharmaceuticals where he raised nearly $40M in venture capital to advance a first-in-class small molecule and first ever industry-sponsored trial in patients with trichotillomania.
Dr. Beyer began his career at Wyeth Pharmaceuticals after completing an internship at the National Institute on Drug Abuse (NIDA) and currently is the Entrepreneur in Residence at Lafayette College. He holds a Ph.D. in Pharmacology & Toxicology from LSU Medical Center and an MBA in Pharmaceutical Management from the Rutgers Business School. Notably, Dr. Beyer has authored more than 70 manuscripts, co-edited 2 books, and has served on the Board of Directors and Scientific Advisory Board of several private companies.
